Literature DB >> 24460274

Detection of recurrence in a surveillance program for epithelial ovarian cancer.

Prapaporn Suprasert1, Wadwilai Chalapati.   

Abstract

Ovarian cancer patients need a surveillance program for the detection of tumor progression after completion of treatment. The methods generally consist of history taking, physical examination, tumor marker monitoring and imaging. However, the details of recurrence detection with each method are not well defined. To clarify this issue, ovarian cancer patients who achieved complete or partial responses and developed tumor progression at the follow up time between January 2004 and December 2010 in University Hospital Chiang Mai, Thailand, were reviewed. Clinical data, CA 125 level and imaging results at the tumor progression time were recorded and analyzed. There were 144 ovarian cancer patients meeting the inclusion criteria with the mean age of 51 years and 62.5% of them were in an advanced stage. Complete response was achieved in 89 patients (61.8%) after primary treatment. The median progression free survival and overall survival were 15.5 months and 37.5 months, respectively. Abnormal symptoms presented in 49.3% of the studied patients and 59.7% developed physical examination abnormalities. In addition, CA 125 was elevated in 89.6% while in 74.3% of tumor progression was identified by CT-scan. Short treatment time period and a high level of CA 125 were significant independent prognostic factors in these patients. In conclusion, careful history taking, physical examination and monitoring of CA 125 levels are important methods for tumor progression detection in a surveillance program for epithelial ovarian cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24460274     DOI: 10.7314/apjcp.2013.14.12.7193

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  1 in total

1.  Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study.

Authors:  Jacqueline Feinberg; Karen Carthew; Emily Webster; Kaity Chang; Nita McNeil; Dennis S Chi; Kara Long Roche; Ginger Gardner; Oliver Zivanovic; Yukio Sonoda
Journal:  Int J Gynecol Cancer       Date:  2021-12-29       Impact factor: 3.437

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.